🇺🇸 FDA
Pipeline program

PEGCETACOPLAN (APL-2)

APL2-103

Phase 1 small_molecule completed

Quick answer

PEGCETACOPLAN (APL-2) for Geographic Atrophy is a Phase 1 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Apellis Pharmaceuticals
Indication
Geographic Atrophy
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials